Palvella Therapeutics (PVLA) EBIT Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 32.96% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -29.67% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -50.81% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 13.47% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.35% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -12.10% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 55.96% |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | 1.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.43% |
| Sep 30, 2025 | 5.78% |
| Jun 30, 2025 | 9.14% |
| Mar 31, 2025 | -1.82% |
| Dec 31, 2024 | 26.51% |
| Sep 30, 2024 | 35.67% |
| Jun 30, 2024 | 44.23% |
| Mar 31, 2024 | 29.68% |
| Dec 31, 2023 | 45.47% |
| Sep 30, 2023 | 3.16% |
| Jun 30, 2023 | 34.68% |
| Mar 31, 2023 | -59.04% |
| Sep 30, 2022 | -61.03% |
| Jun 30, 2022 | -0.27% |
| Mar 31, 2022 | 11.29% |
| Dec 31, 2021 | 4.55% |
| Sep 30, 2021 | -34.56% |
| Jun 30, 2021 | -95.50% |
| Mar 31, 2021 | 14.65% |
| Dec 31, 2020 | -57.58% |
| Sep 30, 2020 | -35.86% |
| Jun 30, 2020 | 16.13% |
| Mar 31, 2020 | 21.61% |
| Dec 31, 2019 | 40.78% |
| Sep 30, 2019 | 22.16% |
| Jun 30, 2019 | -28.27% |
| Mar 31, 2019 | -34.60% |
| Dec 31, 2018 | -70.20% |
| Sep 30, 2018 | -26.23% |
| Jun 30, 2018 | 14.07% |
| Mar 31, 2018 | -30.02% |
| Sep 30, 2017 | -41.21% |
| Jun 30, 2017 | -41.76% |
| Mar 31, 2017 | -128.48% |
| Dec 31, 2016 | -1,328.33% |
| Sep 30, 2016 | -923.51% |
| Jun 30, 2016 | -2,665.53% |